Table 2 Procedural details of ABSORB II trial
From: Bioresorbable scaffolds: a new paradigm in percutaneous coronary intervention
|  | Bioresorbable scaffold group (n = 335) | Metallic stent group (n = 166) | Difference (95 % CI) | p |
|---|---|---|---|---|
Number of lesions | 364 | 182 | Â | Â |
Balloon dilatation prior to device implantation | 364 (100 %) | 180 (99 %) | 1.10 % (−0.21, 3.92) | 0.11 |
Planned overlap with the same type of device | 56 (15 %) | 20 (11 %) | 4.40 % (−1.93, 9.94) | 0.16 |
Additional implantation with the same device | 14 (4 %) | 11 (6.0) | −2.20 % (−6.91, 1.44) | 0.25 |
More than one study device implanted | 70 (19 %) | 27 (15 %) | 4.40 % (−2.57, 10.62) | 0.21 |
Nominal size of study device (mm) | 3.01 (0.31) | 3.05 (0.28) | −0.04 (−0.10, 0.01) | 0.10 |
Balloon dilatation after device implantation | 221 (61 %) | 107 (59 %) | 1.92 % (−6.66, 10.67) | 0.67 |
Nominal diameter of balloon used (mm) | 3.08 (0.34) | 3.16 (0.36) | −0.08 (−0.14, 0.01) | 0.02 |
Maximum balloon pressure used (atm) | 14.23 (3.43) | 15.03 (3.33) | −0.80 (−1.4, −0.2) | 0.01 |
Diameter of balloon used (mm) | 3.29 (0.35) | 3.35 (0.37) | −0.06 (−0.14, 0.02 ) | 0.15 |
Angiographic acute recoil of device following implantation per device (mm) | 0.19 (0.19) | 0.19 (0.18) | −0.00 (−0.04, 0.03) | 0.85 |
Device success | Â | Â | Â | Â |
 Clinical device success | 361 (99 %) | 182 (100 %) | −0.82 % (−2.39, 1.31) | 0.55 |
 Clinical procedural success | 322 (96 %) | 164 (99 %) | −2.68 % (−5.46, 0.80) | 0.16 |